COMMUNIQUÉS West-GlobeNewswire

Nanox Announces Collaboration with Meir Medical Center to Deploy Nanox.ARC for Orthopedic Imaging Clinical Study
14/04/2026
Enhancing emergency triage imaging with Nanox.ARC to improve efficiency and lower radiation dose Collaboration expands clinical evidence base of Nanox.ARC to support broader adoption PETACH TIKVA, Israel, April 14, 2026 [...]
Rivus Pharmaceuticals Announces First Patients Dosed in AMPLIFY Phase 2 Trial for HU6 in MASH
14/04/2026
- Top-line data expected in mid-2027; Actively planning for HU6’s late-stage development in MASH - - HU6 is potential best-in-class oral MASH therapy designed to address unmet needs in MASH through a unique energy [...]
BioVie Announces Abstract Accepted for Presentation at the 2026 American Academy of Neurology Annual Meeting
14/04/2026
CARSON CITY, Nev., April 14, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases [...]
Merakris Therapeutics and iFyber Collaboration Receives Top SAWC Research Award for MTX-001 Wound Healing Study in Human Skin Model
14/04/2026
Phase 2 Clinical Program Underway as Award-Winning Data Strengthen MTX-001’s Position in a Multi-Billion-Dollar Wound Care Market iFyber Partnership Integrates Advanced Tissue Models and Quantitative Bioanalytics to [...]
Hemp Hop Announces 420 Deals in Charlotte, NC with Buy 3, Get 1 Free 2026
14/04/2026
CHARLOTTE, N.C., April 14, 2026 (GLOBE NEWSWIRE) -- Hemp Hop , Charlotte's trusted cannabis brand, is officially launching its biggest 420 sale in Charlotte , NC to date. From April 17–20, 2026 , customers can take [...]
Hinge Bio Announces First Subject Dosed in Phase 1 Trial of HB2198, a Novel B cell Depleting Agent, for Treating Autoimmune Disease
14/04/2026
First-in-human clinical trial underway to evaluate safety, tolerability and pharmacodynamic activity of HB2198 in normal healthy volunteers. A separate Phase 1 trial evaluating HB2198 in patients with Systemic Lupus [...]
Biomerica Launches inFoods® IBS in Canada Through Partnerships with Phoenix Airmid Biomedical and CanAlt Health Labs
14/04/2026
— Represents Biomerica’s First Commercial Entry into the Canadian Market for its Precision, Diagnostic-Guided Therapy — Canada Has One of the Highest IBS Prevalence Rates in the World — an Estimated 18% vs. 11% Globally [...]
Aclarion Receives Pinnacle Award for AI Innovation
14/04/2026
Recognition Follows 2025 HLTH Digital Health Award for Nociscan Award Winning AI Targets a Large and Costly Chronic Low Back Pain Market BROOMFIELD, Colo., April 14, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc ., (“Aclarion [...]
Join Nexalin’s Exclusive Live Investor Webinar and Q&A Session on April 21
14/04/2026
ORLANDO, FL, April 14, 2026 (GLOBE NEWSWIRE) -- RedChip Companies will host an investor webinar on April 21, 2026, at 4:15 p.m. ET with Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW). The exclusive event will feature [...]
Community Routes: Access to Mental Health Care Provides Continued Funding for Mental Health Services at Free & Charitable Clinics
14/04/2026
Supplemental funding helps 11 free & charitable clinics and charitable pharmacies expand mental health care and reach more patients in underserved communities SANTA BARBARA, Calif. and PARSIPPANY, N.J., April 14, [...]
Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts
14/04/2026
Adds dedicated business development leadership to support Tempest’s strategic priorities Will lead China outreach and cross-border partnership efforts To support ongoing partnering discussions for Phase 3-ready [...]
Extendicare Announces Closing of $450 Million Inaugural Offering of Investment Grade Senior Unsecured Notes
14/04/2026
Not for distribution to U.S. news wire services or dissemination in the United States. MARKHAM, Ontario, April 14, 2026 (GLOBE NEWSWIRE) -- Extendicare Inc. (“ Extendicare ” or the “ Company ”) (TSX: EXE) announced [...]
Nxera Pharma’s QUVIVIQ® (daridorexant) 25mg and 50mg Receives Approval in Taiwan for the Treatment of Insomnia
14/04/2026
Nxera’s partner Holling Bio-Pharma Corp. will commercialize QUVIVIQ® in Taiwan, a market with approximately 4–5 million patients, with launch planned during 2026 QUVIVIQ® is approved through Taiwan’s Streamlined Review [...]
Greenwich LifeSciences Provides Update on Financing Strategy
14/04/2026
STAFFORD, Texas, April 14, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is [...]
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2026
14/04/2026
Company Announcement Net sales of DARZALEX ® in the first quarter of 2026 totaled USD 3,964 million Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc [...]
AtaiBeckley to Participate in Upcoming Needham Healthcare Conferences
14/04/2026
Dr. Srinivas Rao, Co-Founder and Chief Executive Officer of AtaiBeckley, will participate in the 25th Annual Needham Virtual Healthcare Conference (April 13 - 16) and the Needham Virtual Psychedelics Forum (April 27) [...]
Kuros Biosciences reports 51% year-over-year increase in sales in the first three months of 2026
14/04/2026
Ad hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences reports 51% year-over-year increase in sales in the first three months of 2026 Financial Highlights Total product sales rose by 51% [...]
Novo Nordisk and OpenAI partner to transform how medicines are discovered and delivered
14/04/2026
Strategic partnership enables upskilling of Novo Nordisk’s workforce and places the company at the forefront of AI transformation in healthcare Novo Nordisk will integrate OpenAI's most advanced AI capabilities globally [...]
Renaissance Pharma Limited, an Essential Pharma company, secures FDA Fast Track Designation and IND clearance for Daretabart (hu1418K322A) in high-risk neuroblastoma
14/04/2026
FDA grants Fast Track Designation for Daretabart (hu1418K322A), recognising the significant unmet medical need in high-risk neuroblastoma and enabling access to accelerated and rolling review FDA clearance of IND [...]

Pages